Page 2093 - Hematology_ Basic Principles and Practice ( PDFDrive )

1856.e6 Part XII Hemostasis and Thrombosis

275. Yonekawa K, Harlan JM: Targeting leukocyte integrins in human 290. Hebbel RP, Yamada O, Moldow CF, et al: Abnormal adherence of sickle
diseases. J Leukoc Biol 77:129, 2005. erythrocytes to cultured vascular endothelium: possible mechanism for
276. Bartt RE: Multiple sclerosis, natalizumab therapy, and progressive microvascular occlusion in sickle cell disease. J Clin Invest 65:154, 1980.
multifocal leukoencephalopathy. Curr Opin Neurol 19:341, 2006. 291. Swerlick RA, Eckman JR, Kumar A, et al: Alpha 4 beta 1-integrin
277. Lebwohl M, Tyring SK, Hamilton TK, et al: A novel targeted T-cell expression on sickle reticulocytes: vascular cell adhesion molecule-1-
modulator, efalizumab, for plaque psoriasis. N Engl J Med 349:2004, dependent binding to endothelium. Blood 82:1891, 1993.
2003. 292. El Nemer W, Wautier MP, Rahuel C, et al: Endothelial Lu/BCAM
278. Polman CH, O’Connor PW, Havrdova E, et al: A randomized, glycoproteins are novel ligands for red blood cell alpha 4 beta 1 integrin:
placebo-controlled trial of natalizumab for relapsing multiple sclerosis. role in adhesion of sickle red blood cells to endothelial cells. Blood
N Engl J Med 354:899, 2006. 109:3544, 2007.
279. Frenette PS, Johnson RC, Hynes RO, et al: Platelets roll on stimulated 293. Kaul DK, Liu XD, Zhang X, et al: Peptides based on alphaV-binding
endothelium in vivo: an interaction mediated by endothelial P-selectin. domains of erythrocyte ICAM-4 inhibit sickle red cell-endothelial
Proc Natl Acad Sci USA 92:7450, 1995. interactions and vaso-occlusion in the microcirculation. Am J Physiol
280. Rosenblum WI, Nelson GH, Wormley B, et al: Role of platelet- Cell Physiol 291:C922, 2006.
endothelial cell adhesion molecule (PECAM) in platelet adhesion/ 294. Turhan A, Weiss LA, Mohandas N, et al: Primary role for adherent
aggregation over injured but not denuded endothelium in vivo and ex leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl
vivo. Stroke 27:709, 1996. Acad Sci USA 99:3047, 2002.
281. Katayama T, Ikeda Y, Handa M, et al: Immunoneutralization of glyco- 295. Minami T, Aird WC: Endothelial cell gene regulation. Trends Cardiovasc
protein Ibalpha attenuates endotoxin-induced interactions of platelets Med 15:174, 2005.
and leukocytes with rat venular endothelium in vivo. Circ Res 86:1031, 296. Raines EW, Ferri N: Thematic review series: the immune system and
2000. atherogenesis. Cytokines affecting endothelial and smooth muscle cells
282. Diacovo TG, Puri KD, Warnock RA, et al: Platelet-mediated lympho- in vascular disease. J Lipid Res 46:1081, 2005.
cyte delivery to high endothelial venules. Science 273:252, 1996. 297. Collins T, Cybulsky MI: NF-kappaB: pivotal mediator or innocent
283. Bombeli T, Schwartz BR, Harlan JM: Adhesion of activated platelets to bystander in atherogenesis? J Clin Invest 107:255, 2001.
endothelial cells: evidence for a GPIIbIIIa-dependent bridging mecha- 298. Khachigian LM: Early growth response-1 in cardiovascular pathobiol-
nism and novel roles for endothelial intercellular adhesion molecule 1 ogy. Circ Res 98:186, 2006.
(ICAM-1), alphavbeta3 integrin, and GPIbalpha. J Exp Med 187:329, 299. Aird WC: The role of the endothelium in severe sepsis and multiple
1998. organ dysfunction syndrome. Blood 101:3765, 2003.
284. Massberg S, Brand K, Gruner S, et al: A critical role of platelet adhesion 300. Libby P, Aikawa M, Jain MK: Vascular endothelium and atherosclerosis.
in the initiation of atherosclerotic lesion formation. J Exp Med 196:887, Handb Exp Pharmacol 176:285, 2006.
2002. 301. Esper RJ, Nordaby RA, Vilarino JO, et al: Endothelial dysfunction: a
285. Dong JF, Moake JL, Nolasco L, et al: ADAMTS-13 rapidly cleaves comprehensive appraisal. Cardiovasc Diabetol 5:4, 2006.
newly secreted ultralarge von Willebrand factor multimers on the 302. Goligorsky MS: Endothelial cell dysfunction: can’t live with it, how to
endothelial surface under flowing conditions. Blood 100:4033, 2002. live without it. Am J Physiol Renal Physiol 288:F871, 2005.
286. Miller LH, Baruch DI, Marsh K, et al: The pathogenic basis of malaria. 303. Pober JS, Min W: Endothelial cell dysfunction, injury and death.
Nature 415:673, 2002. Handb Exp Pharmacol 176:135, 2006.
287. Schofield L, Grau GE: Immunological processes in malaria pathogen- 304. Tousoulis D, Antoniades C, Stefanadis C: Evaluating endothelial func-
esis. Nat Rev Immunol 5:722, 2005. tion in humans: a guide to invasive and non-invasive techniques. Heart
288. van der Heyde HC, Nolan J, Combes V, et al: A unified hypothesis 91:553, 2005.
for the genesis of cerebral malaria: sequestration, inflammation and 305. Constans J, Conri C: Circulating markers of endothelial function in
hemostasis leading to microcirculatory dysfunction. Trends Parasitol cardiovascular disease. Clin Chim Acta 368:33, 2006.
22:503, 2006. 306. Boulanger CM, Amabile N, Tedgui A: Circulating microparticles: a
289. Yipp BG, Anand S, Schollaardt T, et al: Synergism of multiple adhesion potential prognostic marker for atherosclerotic vascular disease. Hyper-
molecules in mediating cytoadherence of Plasmodium falciparum- tension 48:180, 2006.
infected erythrocytes to microvascular endothelial cells under flow. 307. Erdbruegger U, Haubitz M, Woywodt A: Circulating endothelial cells:
Blood 96:2292, 2000. a novel marker of endothelial damage. Clin Chim Acta 373:17, 2006.